LYCOS RETRIEVER 
Pharmaceuticals
built 633 days ago
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Provectus Pharmaceuticals, Inc. (OTCBB: PVCT - News), maintaining its Strong Speculative Buy rating and a 12-month price target of $3.90. The 11-page report by Dutton Associates senior analyst Wayne M. Lottenville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters and Knobias, and other leading financial portals.
Source:
MORE ABOUT
Pharmaceuticals